Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial

BACKGROUND: Progression-free survival was significantly longer in patients who received avelumab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma (aRCC) in a randomized phase III trial. We report long-term safety and efficacy of avelumab plus axitinib as first...

Descripción completa

Detalles Bibliográficos
Autores principales: Larkin, James, Oya, Mototsugu, Martignoni, Marcella, Thistlethwaite, Fiona, Nathan, Paul, Ornstein, Moshe C, Powles, Thomas, Beckermann, Kathryn E, Balar, Arjun V, McDermott, David, Gupta, Sumati, Philips, George K, Gordon, Michael S, Uemura, Hirotsugu, Tomita, Yoshihiko, Wang, Jing, Michelon, Elisabete, di Pietro, Alessandra, Choueiri, Toni K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078905/
https://www.ncbi.nlm.nih.gov/pubmed/36576173
http://dx.doi.org/10.1093/oncolo/oyac243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078905/
https://www.ncbi.nlm.nih.gov/pubmed/36576173
http://dx.doi.org/10.1093/oncolo/oyac243

Ejemplares similares